Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherRevenue (Gross)Shares IssuedShares OutstandingShares Outstanding
Ratios

Abeona Therapeutics (ABEO) Accumulated Depreciation & Amortization (2016 - 2025)

Abeona Therapeutics has reported Accumulated Depreciation & Amortization over the past 14 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $2.5 million for Q4 2025, up 25.0% from a year ago — trailing twelve months through Dec 2025 was $2.5 million (up 25.0% YoY), and the annual figure for FY2025 was $2.5 million, up 25.0%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $2.5 million at Abeona Therapeutics, up from $600000.0 in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for ABEO hit a ceiling of $3.3 million in Q4 2021 and a floor of $500000.0 in Q3 2023.
  • Median Accumulated Depreciation & Amortization over the past 5 years was $800000.0 (2021), compared with a mean of $1.3 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: plummeted 78.26% in 2023 and later skyrocketed 200.0% in 2024.
  • Abeona Therapeutics' Accumulated Depreciation & Amortization stood at $3.3 million in 2021, then dropped by 6.06% to $3.1 million in 2022, then fell by 25.81% to $2.3 million in 2023, then fell by 13.04% to $2.0 million in 2024, then increased by 25.0% to $2.5 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $2.5 million (Q4 2025), $600000.0 (Q3 2025), and $600000.0 (Q2 2025) per Business Quant data.